References
- Voss B L, Hamilton K K, Scott Samara E N, McKee P A. Cyclosporin suppression of endothelial prostacyclin generation. Transplantation 1988; 45: 793
- Zoja C, Furci L, Chilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest 1986; 55: 455
- Hebert D M, Sibley R K, Maner S M. Recurrence of hemolytic uremic syndrome in renal transplant recipients. Kidney Int 1986; 30: 851
- Wolfe J A, McCann R L, Sanfilippo F. Cyclosporin-associated microangiopathy in renal transplantation: a severe but potentially reversible form of early graft injury. Transplantation 1986; 41(4)541
- Shulman H, Striker G, Deeg H J, Kennedy M, Storb R, Thomas D. Nephrotoxicity of cyclosporin A after allogenic marrow transplant. N Engl J Med 1981; 305: 1392
- Bonser R S, Adu D, Franklin I, McMaster P. Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient. Lancet 1984; 2: 1337
- Marshall R J, Sweny P. Haemolytic-uraemic syndrome in recipients of bone marrow transplants not treated with cyclosporin A. Histopathology 1986; 10: 953
- Cerilli G J, Nelsen C, Dorfmann L. Renal homotransplantation in infants and children with the hemolytic-uremic syndrome. Surgery 1972; 71: 66
- Murray B M, Paller M S. Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol 1986; 25: S37
- Hampel G, Kunz F. Cyclosporin A (CyA) induces DNA damage in human glomerular endothelial cells (CEG) (Abstr). Kidney Int 1990; 37(1)483
- Kon V, Sugiura M, Inagami T, Hoover R L, Fogo A, Harvie B R, Ichikawa I. Cyclosporin (Cy) causes endothelin-dependent acute renal failure (Abstr). Kidney Int 1990; 37(1)486
- Neild G H, Rocchi G, Imberti L, Fumagalli F, Brown Z, Remuzzi G, Williams D G. Effect of cyclosporin A on prostacyclin synthesis by vascular tissue. Thromb Res 1983; 32: 373
- Stahl R AK, Adler S, Baker P J, Johnson R J, Chen Y -P, Pritzl P, Couser W G. Cyclosporin A inhibits prostaglandin E2 formation by rat mesangial cells in culture. Kidney to 1989; 35: 1161
- Perico N, Benigni A, Zoja C, Delaini F, Remuzzi G. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am J Physiol 1986; 251: F581
- Elzinga L, Kelly V E, Houghton D C, Bennett W M. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporin. Transplantation 1987; 43(2)271
- Paller M S. Effects of the prostaglandin E1 analog misoprostol on cyclosporin nephrotoxicity. Transplantation 1988; 45(6)1126
- Cooper P, Mason J, Donatsch P, Rickenbacher U. Prostanoid excretion in rats treated with “Sandimmune.” (Abstr). Kidney Int 1990; 37(1)594
- MacIntyre D E, Pearson J D, Gordon J L. Localisation and stimulation of prostacyclin production in vascular cells. Nature 1978; 271: 549
- Leithner C, Winter M, Silbauer K, Wagner O, Pinggera W, Sinzinger H. Enhanced prostacyclin availability of blood vessels in uraemic humans and rats. Proc Eur Dial Trans Assoc 1978; 15: 418
- Remuzzi G, Livio M, Cavenaghi A E, Marchesi D, Mecca G, Donati M B, de Gaetano G. Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. a hypothesis. Thromb Res 1978; 13: 531
- Remuzzi G, Marchesi D, Mecca G, Misiani R, Livio M, de Gaetano G. Haemolytic uraemic syndrome: Deficiency of plasma factor(s) regulating prostacyclin activity?. Lancet 1978; 2: 871
- Dyck R F, Kappell J E, Sheridan D, Card R T. Reversible cyclosporine-associated hemolytic uremic syndrome in a renal transplant recipient: a role for a platelet aggregating factor?. Transplant Proc 1986; 18(1)228
- Licciardello J TW, Moake J L, Rudy C K, Karp D D, Hong W K. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985; 42: 296
- Hamilton D V, Calne R Y, Evans D B. Haemolytic-uraemic syndrome and cyclosporin A (letter). Lancet 1982; 2: 151